申请人:Novo Nordisk A/S
公开号:US05177077A1
公开(公告)日:1993-01-05
A disubstituted piperazine compound having the formula I ##STR1## wherein R.sup.1 is thienyl or phenyl, which may be substituted with C.sub.1-6 -alkyl or halogen, and R.sup.2 is thienyl, which may be substituted with C.sub.1-6 -alkyl or halogen, and R.sup.3 is C.sub.1-8 -alkyl, C.sub.3-8 -alkenyl or C.sub.3-8 -cycloalkyl which all may be substituted with hydroxy, oximino or keto in any position giving a stable tertiary amine or R.sup.3 is C.sub.1-8 -alkyl or C.sub.3-8 -alkenyl which in any position may be substituted as above, but is terminally substituted with phenoxy, phenyl, thienyl, furyl, methoxy or --CN and pharmaceutically acceptable acid addition salts thereof. The compounds are useful in the treatment of mental disorders in which a dopaminergic deficit is implicated.
具有以下式子I的双取代哌嗪化合物:##STR1## 其中R.sup.1是噻吩基或苯基,可用C.sub.1-6-烷基或卤素取代,R.sup.2是噻吩基,可用C.sub.1-6-烷基或卤素取代,R.sup.3是C.sub.1-8-烷基、C.sub.3-8-烯基或C.sub.3-8-环烷基,均可在任何位置用羟基、肟基或酮基取代,形成稳定的三级胺,或者R.sup.3是C.sub.1-8-烷基或C.sub.3-8-烯基,在任何位置都可以像上面那样取代,但是在末端用苯氧基、苯基、噻吩基、呋喃基、甲氧基或--CN取代,并且与药物相容的酸加盐。该化合物在治疗涉及多巴胺缺乏的精神障碍方面有用。